On the morning of October 8, Ma Zhenkun, founder and president of TenNor Therapeutics, stepped into the Zhongshan Life Science Park with his colleagues to inspect the implementation of the company's project.

In 2013, after resigning from the TB Alliance, Ma Zhenkun returned to China and founded TenNor Therapeutics. The company focuses on diseases related to bacterial infections and metabolism as well as on new drug research and development. Currently, three of its products have entered the later clinical trial stage.

According to a publication in a top global comprehensive medical journal, the world's first-in-class innovative drug Rifasutenizol (TNP-2198) developed by TenNor Therapeutics is the first in the world over 30 years specifically developed for the treatment of Helicobacter pylori. This product is expected to overcome the challenge of antibiotic resistance and provide a novel Chinese solution for Helicobacter pylori infection.

In September of this year, TenNor Therapeutics signed an investment agreement with Zhongshan Venture Capital, a subsidiary of Zhongshan Investment Holdings, to establish a project in Zhongshan. The financing funds will be used for the commercialization of TNP-2198 and advancing the R&D and clinical trials of TenNor Therapeutics' other new drug products.

According to the agreement, TenNor Therapeutics will settle its project in the Zhongshan Life Science Park. At least 300 million yuan will be invested in the construction of a production base for core pipelines with a settlement center.